TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29935086

Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Assessment-Only (AO) Control
Number of subjects: 164
Study: 26700096

Group type: EXPERIMENTAL
Intervention: 2 g/day of fish oil (0.6 g/day of EPA and DHA) for 9 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG) received neither fish oil nor placebo
Number of subjects: 30
Study: 25283757

Group type: EXPERIMENTAL
Intervention: Patient education (video, brochure, questionnaire)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control (brochure only)
Number of subjects: 319
Study: 22763392

Group type: EXPERIMENTAL
Intervention: MoleMate system (SIAscopy with primary care scoring algorithm)
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: MoleMate system
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Best practice alone (control group)
Number of subjects: 1297
Study: 20582542

Group type: EXPERIMENTAL
Intervention: Preincisional parecoxib (40 mg IV 30 min before skin incision)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Postincisional parecoxib (40 mg IV 30 min after skin incision)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups received patient-controlled analgesia (PCA) morphine
Number of subjects: 41
Study: 17394704

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 15679759

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12358621

Group type: EXPERIMENTAL
Intervention: Artemisinin (40 mg/kg over 3 days) plus placebo chloroquine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg over 3 days) plus placebo artemisinin
Number of subjects: 240
Study: 10366800

Group type: EXPERIMENTAL
Intervention: SCF plus G-CSF
Number of subjects: 102

Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 102
Study: 9723152

Group type: EXPERIMENTAL
Intervention: D-fenfluramine (D-FEN)
Number of subjects: 28
Study: 1928212

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine
Number of subjects: 0
Study: 6412223

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study: 30256314

Group type: EXPERIMENTAL
Intervention: BCG-Russia alone
Number of subjects: 3075

Group type: EXPERIMENTAL
Intervention: BCG-Russia with OPV
Number of subjects: 3075

Group type: COMPARATOR
Intervention: Control group (no vaccination before 28 days)
Number of subjects: 3075
Study: 29603114

Group type: EXPERIMENTAL
Intervention: Routine labor epidural analgesia (EA)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Pain relief on maternal request only (Control)
Number of subjects: 488
Study: 26661521

Group type: EXPERIMENTAL
Intervention: 940-nm EVLA
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 1470-nm EVLA
Number of subjects: 142
Study: 24740484

Group type: EXPERIMENTAL
Intervention: Transcutaneous functional electrical stimulation (FES); 15 children, 15-minute sessions, 3 times per week for 15 courses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation; 15 children
Number of subjects: 30
Study: 23074206

Group type: EXPERIMENTAL
Intervention: PF‐04523655 3‐mg intravitreal injections
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PF‐04523655 0.4‐mg intravitreal injections
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PF‐04523655 1‐mg intravitreal injections
Number of subjects: 184

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 184
Study: 20925948

Group type: EXPERIMENTAL
Intervention: Tailored home-based exercise twice weekly
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Group-based exercise twice weekly in rehabilitation center
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care and information of exercise and nutrition (Control)
Number of subjects: 210
Study: 18410585

Group type: EXPERIMENTAL
Intervention: 2.5 mg melatonin and 100 mg SB‐73
Number of subjects: 145

Group type: COMPARATOR
Intervention: 200 mg Acyclovir
Number of subjects: 145
Study: 16103288

Group type: EXPERIMENTAL
Intervention: Glycolic copolymer staple-line reinforcement sleeves
Number of subjects: 34

Group type: COMPARATOR
Intervention: No reinforcement (control group)
Number of subjects: 34
Study: 11962225

Group type: EXPERIMENTAL
Intervention: Back education program for intervention children
Number of subjects: 706
Study: 10636595

Group type: EXPERIMENTAL
Intervention: nSIPPV
Number of subjects: 11

Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 11
Study: 7488479

Group type: EXPERIMENTAL
Intervention: FIO2 of 1.0 (group O)
Number of subjects: 34

Group type: COMPARATOR
Intervention: FIO2 of 0.35 (group A)
Number of subjects: 34
Study: 1957409

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg, supplemented with half of the initial dosage if necessary)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg, supplemented with half of the initial dosage if necessary)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study: 7343284

Group type: EXPERIMENTAL
Intervention: 5,000 IU heparin-dihydroergotamine mesylate (Dihydergot)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 31674810

Group type: EXPERIMENTAL
Intervention: HTC (hyperventilation + thigh-cuff deflation)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Con (control transition)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Thigh-cuff deflation
Number of subjects: 19
Study: 27819489

Group type: EXPERIMENTAL
Intervention: Progesterone (1 mg kg‐1 per 12 hours for 5 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 26449164

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for 48 weeks followed by treatment interruption (TI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-cell exhaustion markers (PD-1, Tim-3, Lag-3) measured prior to ART
Number of subjects: 0
Study: 23726041

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 500 mg
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Lebrikizumab (all doses)
Number of subjects: 212
Study: 21376885

Group type: EXPERIMENTAL
Intervention: Self-explanation questionnaire
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relapse-prevention questionnaire
Number of subjects: 30

Group type: COMPARATOR
Intervention: Familiarization flight (control group)
Number of subjects: 30
Study: 19711440

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) levels of 140-150 mmHg
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) levels > 150 - < or = 160 mmHg
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) levels > 160 mmHg
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Angina reported in the 4 weeks prior to a protocol visit
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Female gender, black race, history of smoking, diabetes, myocardial infarction, stroke, and cancer
Number of subjects: 22576
Study: 17610805

Group type: EXPERIMENTAL
Intervention: Meal-based self-monitoring of blood glucose (SMBG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapies targeting postprandial hyperglycemia
Number of subjects: 0
Study: 15096971

Group type: EXPERIMENTAL
Intervention: N-13 ammonia (600 MBq or 16 mCi) administered intravenously
Number of subjects: 65
Study: 11243303

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 4 mg to 8 mg once daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Enalapril (E) 10 mg to 20 mg once daily
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 227
Study: 9562226

Group type: EXPERIMENTAL
Intervention: Inhaled steroid plus theophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doubling the steroid dose
Number of subjects: 0
Study: 8021901

Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure (BP) at home for 14 days (mean of 26.7 measurements)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Office blood pressure measurement before and after the two-week period
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Morning self-measured BP
Number of subjects: 503

Group type: COMPARATOR
Intervention: Second office BP measurement
Number of subjects: 503
Study: 2302376

Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1% midazolam
Number of subjects: 40
Study: 7006616

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30882927

Group type: EXPERIMENTAL
Intervention: Fresh RBC units
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard storage age RBC units
Number of subjects: 100
Study: 28576451

Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (immediate treatment group)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (deferred treatment group)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 235

Group type: COMPARATOR
Intervention: Deferred treatment group
Number of subjects: 235
Study: 26070127

Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (estriol 50 μg/g gel, twice a week for 12 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hyaluronic acid vaginal gel (once a day for 12 weeks)
Number of subjects: 31
Study: 23581825

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tryptophan-balanced control condition
Number of subjects: 40
Study: 21548209

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil every other day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin E at 100 mg once a day for 12 weeks (Control)
Number of subjects: 60
Study: 18949763

Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention Program (PIP), n = 60, consisting of eight individual sessions over 4 months.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard care (CG), n = 55.
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: PIP (IG)
Number of subjects: 115
Study: 17768270

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive psychotherapy (SPT)
Number of subjects: 80
Study: 15485728

Group type: EXPERIMENTAL
Intervention: Attempted telephone reminder (n=256)
Number of subjects: 703

Group type: COMPARATOR
Intervention: No reminder (n=242)
Number of subjects: 703
Study: 11241060

Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 20
Study: 9494478

Group type: EXPERIMENTAL
Intervention: Nonionic contrast material
Number of subjects: 109

Group type: COMPARATOR
Intervention: Ionic contrast material
Number of subjects: 109
Study: 8067497

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day for 1 week, then 40 mg/day for 5 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3058752

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthrinse (Corsodyl)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: sanguinarine-zinc mouthrinse (Veadent)
Number of subjects: 14
Study: 123880

Group type: EXPERIMENTAL
Intervention: Arteparon forte
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 106
Study: 31006690

Group type: EXPERIMENTAL
Intervention: Occupation-based intervention (Experimental group, n = 23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Action focusing intervention (Control group, n = 20)
Number of subjects: 43
Study: 28929203

Group type: EXPERIMENTAL
Intervention: Fluoride-containing toothpaste (Colgate Total®)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Novamin-containing toothpaste (Sensodyne® Repair and Protect)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Probiotic-containing toothpaste (GD Probiotic Toothpaste®)
Number of subjects: 45
Study: 26181252

Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: lapatinib
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: combination of trastuzumab and lapatinib
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: all treatment groups
Number of subjects: 455
Study: 23625480

Group type: EXPERIMENTAL
Intervention: Dopamine alone (Group A, n = 46)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dopamine and dobutamine (Group B, n = 40)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dopamine, dobutamine, and adrenaline (Group C, n = 36)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adrenaline alone (Group D, n = 32)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (Group E, n = 46)
Number of subjects: 200
Study: 20692769

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 54
Study: 19420195

Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam lysine (AZLI) 75 mg three times daily for 28 days
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 16938760

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 40
Study: 15253732

Group type: EXPERIMENTAL
Intervention: Ramipril (6 mg/m2)
Number of subjects: 397
Study: 11236072

Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg/day
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Citalopram (all doses)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg and 20 mg
Number of subjects: 401
Study: 9305229

Group type: EXPERIMENTAL
Intervention: Live active yogurt containing L. acidophilus (225 g twice daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (yogurt without L. acidophilus)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Live active yogurt containing L. acidophilus
Number of subjects: 15
Study: 7906085

Group type: EXPERIMENTAL
Intervention: Collagen sponge loaded with gentamicin
Number of subjects: 20

Group type: COMPARATOR
Intervention: PMMA beads loaded with gentamicin
Number of subjects: 20
Study: 3084344

Group type: EXPERIMENTAL
Intervention: Bowel rest with parenteral nutrition
Number of subjects: 47

Group type: COMPARATOR
Intervention: Oral diet
Number of subjects: 47
Study: 29385769

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 63
Study: 25277730

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 172

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 172
Study: 25495543

Group type: EXPERIMENTAL
Intervention: Learning and coping strategies incorporated into standard care in cardiac rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation program (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning and coping strategies
Number of subjects: 0
Study: 22795063

Group type: EXPERIMENTAL
Intervention: Moderate potassium cold blood cardioplegia (K+, 10 mmol/L)
Number of subjects: 68

Group type: COMPARATOR
Intervention: High potassium cold blood cardioplegia (K+, 20 mmol/L)
Number of subjects: 68
Study: 20361464

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study: 19477776

Group type: EXPERIMENTAL
Intervention: Androgen ablation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Literature on female breast cancer patients treated with hormones
Number of subjects: 0
Study: 16158696

Group type: EXPERIMENTAL
Intervention: Specific Practice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Variable Practice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 12520156

Group type: EXPERIMENTAL
Intervention: Phase III comprehensive cardiac rehabilitation (CR) for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 38
Study: 10393675

Group type: EXPERIMENTAL
Intervention: Direct coronary angioplasty
Number of subjects: 565

Group type: COMPARATOR
Intervention: Patients assigned to angioplasty who never underwent the procedure
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Time from enrollment to first balloon inflation
Number of subjects: 565
Study: 8695998

Group type: EXPERIMENTAL
Intervention: Fibreoptic phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: White light phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blue light phototherapy
Number of subjects: 0
Study: 1852979

Group type: EXPERIMENTAL
Intervention: 2 weeks oral digoxin administration
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6334320

Group type: EXPERIMENTAL
Intervention: Erythromycin base as enteric coated pellets (2 X 250 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Erythromycin stearate tablet (1 X 500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate sachet (1 X 500 mg)
Number of subjects: 12
Study: 31745048

Group type: EXPERIMENTAL
Intervention: Mini-implant anchorage system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional accentuated compensating curve archwire
Number of subjects: 20
Study: 30470323

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (Pain Course)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Medically unexplained etiology
Number of subjects: 471

Group type: COMPARATOR
Intervention: Medically explained etiology
Number of subjects: 471
Study: 27631178

Group type: EXPERIMENTAL
Intervention: Calcitriol supplementation (25 µg) plus hypocaloric diet
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo plus hypocaloric diet
Number of subjects: 73
Study: 23682797

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification including supervised exercise sessions
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study: 21950736

Group type: EXPERIMENTAL
Intervention: Caffeine (2 × 200 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Modafinil (2 × 100 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prolonged wakefulness
Number of subjects: 82
Study: 20659063

Group type: EXPERIMENTAL
Intervention: Reimbursement of smoking cessation support (SCS)
Number of subjects: 0
Study: 17614214

Group type: EXPERIMENTAL
Intervention: Intervention materials based on the transtheoretical model
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Intervention materials for smokers in precontemplation
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Intervention materials for smokers in contemplation, preparation, action, and maintenance
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Tailoring for precontemplation
Number of subjects: 1044
Study: 15663566

Group type: EXPERIMENTAL
Intervention: Chlorofluorocarbon‐driven beclomethasone diproprionate (BDP) 400 microg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrofluoroalkane‐driven BDP, 200 microg b.i.d.
Number of subjects: 0
Study: 12398790

Group type: EXPERIMENTAL
Intervention: Universal assessment by a study nurse
Number of subjects: 33000

Group type: EXPERIMENTAL
Intervention: Targeted assessment based on pre-determined problems
Number of subjects: 33000

Group type: EXPERIMENTAL
Intervention: Management by primary care team (PC)
Number of subjects: 33000

Group type: EXPERIMENTAL
Intervention: Management by multidisciplinary geriatric assessment team (GM)
Number of subjects: 33000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33000
Study: 9792578

Group type: EXPERIMENTAL
Intervention: CPAP treatment (continuous positive airway pressure)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lower CPAP pressure during T2 to T4
Number of subjects: 20

Group type: COMPARATOR
Intervention: Daytime alertness
Number of subjects: 20
Study: 7706024

Group type: EXPERIMENTAL
Intervention: Blue-on-yellow (B-Y) perimetry
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Yellow-on-yellow (Y-Y) perimetry
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: White-on-white (W-W) perimetry
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior subcapsular cataract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anterior cortical cataract
Number of subjects: 60
Study: 2654321

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 65221

Group type: EXPERIMENTAL
Intervention: MOPP and ABDV chemotherapy with local radiotherapy
Number of subjects: 37
Study: 30352537

Group type: EXPERIMENTAL
Intervention: Preoperative oral morphine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28723689

Group type: EXPERIMENTAL
Intervention: Benifuuki tea
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Yabukita tea
Number of subjects: 32

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 32
Study: 25448102

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 105

Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 105
Study: 23333117

Group type: COMPARATOR
Intervention: Standard chemotherapy (carboplatin and paclitaxel)
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Bevacizumab with standard chemotherapy
Number of subjects: 1528
Study: 21659011

Group type: EXPERIMENTAL
Intervention: Dorsal nail fixation (group 1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Locked volar plate fixation (group 2)
Number of subjects: 31